Optimizing Postoperative Betablockade with Landiolol on top of oral betablocker to prevent New-Onset Atrial Fibrillation Following Cardiac Surgery in Caucasian patients: A multicenter, randomized, double-blind study.

开始日期2026-09-01

申办/合作机构-

NCT07846995

/ CompletedN/AIIT

Pretreatment Haemodynamic Prediction of Recorded Early Circulatory Deterioration After Documented Short-Acting Beta-Blocker Treatment in Intensive Care: A Retrospective Multicohort Study

This retrospective observational study used existing intensive care records to examine whether heart rate and blood pressure measured before short-acting beta-blocker treatment could help predict early signs of worsening circulation recorded after treatment.
The study included patients who had received intravenous esmolol or landiolol during routine care. Researchers did not assign treatment or change patient care. The main analysis used records from Zhongshan Hospital, Fudan University. Additional intensive care databases were used to evaluate whether a prediction model developed at this hospital could be applied to other patient populations.
The main questions were whether pretreatment heart rate and blood pressure could predict recorded circulatory changes, whether combining these measurements improved prediction over simpler blood pressure measures, and whether differences in blood pressure monitoring affected the findings.
The main outcome combined a recorded fall in blood pressure, initiation or escalation of norepinephrine (a medicine used to support blood pressure), or early discontinuation of the same beta-blocker. Blood pressure and norepinephrine changes were assessed during the first three hours after the treatment index, and drug discontinuation during the first hour. External database analyses focused on recorded low blood pressure during the first three hours.
The study evaluated prediction among patients who had already received treatment. It was not designed to determine whether beta-blockers caused these events or whether a patient should receive a beta-blocker. Data collection and the analyses described here were completed before registration.

开始日期2026-08-01

申办/合作机构

复旦大学附属中山医院

100 项与盐酸兰地洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸兰地洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸兰地洛尔相关的专利（医药）

登录后查看更多信息

445

项与盐酸兰地洛尔相关的文献（医药）

2026-11-01·Anaesthesia Critical Care & Pain Medicine

Landiolol for atrial fibrillation after cardiac surgery: from prevention to treatment

作者: Mongardon, Nicolas ; Fischer, Marc-Olivier ; Rozec, Bertrand

2026-11-01·Anaesthesia Critical Care & Pain Medicine

Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

Review

作者: Shawky, Ahmed ; Awad, Ayman K ; Akoum, Atef ; Badran, Ahmed Samy ; Medhat, Ahmed ; El-Diasty, Mohammad ; Elbahloul, Mohammed A

BACKGROUND:

Postoperative atrial fibrillation (POAF) occurs in up to 30% of patients undergoing cardiac surgery. Landiolol is an ultrashort-acting, highly β1-selective intravenous beta blocker. We aimed to investigate the effect of landiolol in the prevention of POAF.

METHODS:

Electronic databases were searched for randomized clinical trials (RCTs) evaluating landiolol for the prevention of POAF. Dichotomous outcomes were reported as odds ratios (ORs) and continuous outcomes as mean differences (MDs), each with 95% confidence intervals. The primary outcome was the incidence of POAF.

RESULTS:

A total of 11 RCTs, including 1,264 patients, were analyzed. Landiolol was associated with a significantly lower incidence of POAF compared with the control group (OR: 0.35, 95% CI: 0.23-0.53, p < 0.01). There were no significant differences between landiolol and the control group in terms of hospital mortality, length of hospital stay, heart failure, or major complications.

CONCLUSIONS:

Landiolol appears to be an effective agent for the prevention of POAF in patients undergoing cardiac surgeries. Large-scale, multi-ethnic RCTs are needed to confirm these findings.

2026-09-01·JACC. Case reports

Microaxial Flow Pump and Ivabradine for Tachycardia-Induced Cardiogenic Shock Caused by Automatic Atrial Tachycardia

Article

作者: Nakasuka, Kosuke ; Asaumi, Yasuhide ; Honda, Satoshi ; Muto, Kosuke ; Noguchi, Teruo

BACKGROUND:

Management of tachycardia-induced cardiomyopathy (TIC) complicated by cardiogenic shock is challenging because rate control and hemodynamic stabilization must be achieved simultaneously.

CASE SUMMARY:

A 32-year-old woman was transferred because of refractory narrow QRS tachycardia at a rate of 140 beats/min and cardiogenic shock with a left ventricular ejection fraction of 10% to 15%. P-wave morphology, failure to terminate with cardioversion, and a warm-up pattern suggested automatic atrial tachycardia originating near the sinus node. Severe left ventricular dysfunction was considered TIC. Under percutaneous microaxial flow pump support, ivabradine and landiolol achieved rate control without hemodynamic deterioration. Left ventricular function improved, allowing microaxial flow pump weaning and transition to oral bisoprolol.

DISCUSSION:

Microaxial flow pump-supported pharmacological rate control may be a useful bridge-to-recovery strategy for this condition.

TAKE-HOME MESSAGES:

A microaxial flow pump may provide hemodynamic support, facilitating safe rate control and myocardial recovery in TIC complicated by cardiogenic shock. Ivabradine may be useful when beta-blockers are difficult to initiate.

114

项与盐酸兰地洛尔相关的新闻（医药）

2026-10-16

·灵与新

让药物“到点下班”：软药如何把疗效留在病灶、把风险降到全身之外？

导语：一种药物能不能既在病灶处发挥作用，又在离开目标组织后迅速失活？“软药”设计试图回答这个问题。它不是把药物做得更弱，而是让药物在需要的地方保持活性，在不需要的地方按预设路径及时“关机”。本文依据 Tracey Pirali 等发表于《Nature Reviews Drug Discovery》的综述“Soft drugs: design principles and topical applications”编译整理。一、为什么需要“软药”？药物研发中，一个棘手的问题是：即使药物精准命中了目标，药物在全身循环后仍可能作用于其他组织，或在不需要的时间继续发挥作用。提高靶点选择性有帮助，却无法解决所有问题——有时风险来自药物本身在全身的暴露过久。软药（soft drug）的思路，是把“可预测的失活”提前写进分子设计：药物先以活性形式抵达作用部位、完成治疗任务；随后在离开目标组织或进入循环后，经预设的代谢路径转化为药理活性很低、无毒且容易清除的代谢物。目标是让局部疗效与全身风险尽可能分开。软药和前药，方向正好相反：前药通常先以无活性或低活性形式给药，再经体内转化释放活性药物；软药则是给入时已经有活性，之后再被代谢“关掉”。两者都涉及体内转化，但设计方向不同：前药常用于改善溶解度、吸收或递送；软药着重于可控地缩短作用时间、减少全身暴露。相关策略：前软药先以不活跃形式递送，在目标组织激活，之后再快速失活；双软药/超软药则通过一个或多个代谢步骤（常涉及血液和肝脏）进一步压低全身暴露。图1：前药、软药、前软药及双软药/超软药的设计策略二、怎样才算设计成功？给分子装上一个容易代谢的“软点”（soft spot）还不够。还需满足以下几项关键要求： 1. 软点不能明显损害药物与靶点结合所需的活性； 2. 失活路径要可预测、可调节，并尽量避免药物相互作用或个体差异造成不可控的暴露； 3. 生成的代谢物应当药理活性低、无毒，并能被机体清除； 4. 最终要用体内药代动力学证据证明：药物到达作用部位时足够稳定，离开后又能及时失活。常见软点包括容易被酯酶水解的酯键，也包括可被氧化或进一步结合代谢的结构。选择哪条路径，取决于目标组织、给药途径和所需作用时长。体外代谢快不等于体内就安全有效，局部组织中的药物浓度、停留时间和代谢速度都要一起评估。系统给药的经典例子是艾司洛尔（esmolol）。它在β受体阻滞剂骨架上引入易水解的酯键，发挥作用后可被血液中的酯酶迅速转化。停药后药效较快消退，适合需要精细调节的急性心血管场景。瑞芬太尼、兰地洛尔和瑞马唑仑也是综述列举的临床软药案例。图2、软药设计中常见的水解、氧化及其他代谢/化学失活途径。三、局部用药：让药效停留在目标组织局部软药的共同目标，是在皮肤、肺、肠道或眼部发挥作用，同时降低进入全身循环后产生不良作用的机会。不同组织的屏障、酶和给药方式差异很大，因此“局部稳定、全身易失活”必须针对具体场景设计。图3：局部用药与系统给药的组织分布和失活路径，以及不同局部给药部位。1、皮肤：局部疗效与全身暴露之间的平衡皮肤病往往局限于皮肤，局部给药有机会减少不必要的全身暴露。综述重点讨论了多种已上市药物：克拉司酮（clascoterone）用于痤疮，局部作用于雄激素受体；氯化索非那新（sofpironium bromide）用于多汗症；克立硼罗（crisaborole）用于特应性皮炎。它们的结构或代谢特征有助于降低系统性药理作用。皮肤软药的开发仍面临“剂量到不了病灶”与“局部代谢过快”这两类相反问题。若药物还没穿透到作用层就已失活，疗效会受损；若吸收后失活不足，则系统暴露仍可能带来风险。因此，皮肤渗透、局部停留和代谢速率必须协同优化。2、吸入给药：肺部有效，全身尽快清除吸入给药可把药物直接送到呼吸道，但肺组织和血液中的代谢环境并不相同。阿克利定（aclidinium）等药物展示了吸入治疗与快速失活设计的结合。该综述也讨论了在研的支气管扩张剂、抗炎药和免疫调节剂，以及面向局部肺部作用的软药和软 PROTAC 设计。不过，局部给药并不自动等于局部安全。肺部靶点被激活后可能触发全身性生物信号；在吸入 TLR7 激动剂的研究中，即使药物设计用于限制系统暴露，肺部启动的下游细胞因子反应仍可能引起类似流感的不适。这说明药代动力学上的“软”，不能替代对药效学机制的评估。3、肠道：局部作用，也要顾及肠壁和微生物群肠道疾病的理想药物可能需要穿过肠上皮、作用于细胞内靶点，同时避免进入全身后造成免疫抑制或其他毒性。在该综述中介绍了肠道感染、炎症性肠病、结直肠癌预防和代谢靶点等方向的候选药物。其中，NVP-EDI048 是用于隐孢子虫感染的 PI(4)K 抑制剂。其设计旨在保留肠道抗寄生虫作用、减少系统暴露；为进入 II 期临床阶段的候选药物。AKP-001等研究则探索通过代谢失活限制p38 MAPK 抑制剂的全身作用。肠道菌群本身也可能参与药物转化，为“按部位控制药物活性”增加了新的变量。4、眼科：眼内不同区室，代谢速度也不同眼药水使用方便，但药液会受到泪液更新、眨眼和鼻泪道引流的影响；一部分药物还可能进入全身循环。眼部不同组织的代谢能力也不一样，单靠血浆或常规体外实验，未必能预测药物在眼内的表现。氯替泼诺依碳酸酯（loteprednol etabonate）是已上市眼科软药例子，常用于眼部炎症。研究者也在探索用于青光眼的软性β受体阻滞剂和Rho激酶抑制剂，希望保留降眼压作用，同时减少结膜充血等局部不良反应。候选药物如 sovesudil 的例子说明，软点在眼表和眼内组织的稳定性差异，可能决定疗效与耐受性的平衡。四、软药研发的边界与挑战1、失活速度要“刚刚好” 代谢太快，药物可能来不及进入组织或结合靶点；代谢太慢，又无法有效减少全身暴露。这个合适的动力学窗口会因组织、给药途径和适应症而改变，不能用一种通用的半衰期标准来判断。2、动物数据不一定能预测人体不同物种的代谢酶分布存在差异。啮齿动物血浆中的羧酸酯酶活性较高，而人体血浆中相关水解能力更多依赖丁酰胆碱酯酶、对氧磷酶等酶系统。若只根据动物血浆实验推断人体失活速度，可能高估或低估实际效果。早期使用人体血浆、全血、肝脏和目标组织样本验证代谢路径，有助于降低转化风险。3、代谢安全不等于机制安全软药主要解决的是暴露相关风险，不能消除靶点本身造成的生理效应。即使药物很快从血液中失活，局部启动的信号仍可能扩散并产生不良反应。代谢物的活性、局部刺激性、制剂稳定性和给药装置兼容性，也都需要纳入开发评估。4、监管和临床证据仍需逐案建立软药不是独立的监管类别。开发者仍需在相应给药途径和适应证框架下，证明药物如何在目标组织维持作用、离开后如何失活，以及代谢物和全身暴露为何可接受。组织相关药代/药效研究、人体相关模型、器官芯片和预测性 ADME 工具可能帮助提高成功率，但目前仍需要扎实的实验验证。结语：把药物的“开关”设计进分子软药设计的核心，不是单纯缩短药物在体内的存在时间，而是让药物在正确的部位和时间发挥作用，并在离开后沿着可预测的路径失活。艾司洛尔、瑞芬太尼以及部分皮肤、吸入和眼科药物，展示了这一理念的临床价值；在研的肠道和局部递送候选药物，则拓展了它可能适用的范围。这套策略的成败，最终取决于对组织分布、代谢速度、靶点生物学和制剂特性的共同理解。随着人体相关代谢模型、组织暴露测量和预测工具的发展，软药有望成为开发局部治疗、降低系统风险的一种更成熟的分子设计方法。 Reference：Tracey Pirali, Alessandro Accetta, Jarkko Rautio & Laura Carzaniga. Soft drugs: design principles and topical applications. Nature Reviews Drug Discovery. DOI: 10.1038/s41573-026-01535-y；https://doi.org/10.1038/s41573-026-01535-y。

2026-10-08

·BioSpace

Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)

Montreal, Quebec and Vienna, Austria--(News - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to Pr SIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker. Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial fibrillation and atrial flutter, in perioperative, postoperative, or other acute circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. With an elimination half-life of approximately 4 minutes, SIBBORAN allows physicians to titrate heart rate control to the individual patient's response, with rapidly reversible effects following discontinuation. These characteristics support its use when short-term, adjustable heart rate control is needed in monitored acute-care settings. For complete prescribing information, including contraindications, warnings and precautions, please consult the Product Monograph. "Landiolol is unique because it allows precise, real-time titration to a target heart rate, with rapid adjustment as the patient's condition changes," said William F. McIntyre, MD, PhD, FRCPC, cardiac electrophysiologist at Hamilton Health Sciences and St. Joseph's Healthcare Hamilton, and Assistant Professor at McMaster University. Under the terms of the agreement, Enoumena will lead Canadian commercialization activities, including institutional market access, hospital formulary strategy, medical stakeholder engagement, and field execution. AOP Health is responsible for regulatory affairs, pharmacovigilance, quality, manufacturing, and supply. "This agreement is a defining milestone for Enoumena," said Peter Melnyk, PhD, President and CEO of Enoumena Therapeutics. "Our model is built on pairing focused Canadian execution with innovative international pharmaceutical partners. SIBBORAN is a highly specialized therapy that requires a deep understanding of the critical care setting. We are very pleased to partner with AOP Health to support reliable access to this important therapeutic option for Canadian clinicians and their patients." Michael Kindell, Area Director Intercontinental at AOP Health, added: "We are extremely pleased to partner with Enoumena and look forward to working together to make SIBBORAN available to patients in Canada. By combining AOP Health's expertise in developing therapies for rare and critical diseases with Enoumena's strong local capabilities and market knowledge, we believe we can accelerate access to treatment and make a meaningful difference for patients, healthcare professionals, and healthcare systems alike." About Enoumena Therapeutics Inc. Enoumena Therapeutics Inc. is a Canadian specialty pharmaceutical company that partners with international pharmaceutical and biotechnology companies to commercialize innovative medicines in Canada. Enoumena combines Canadian market access, medical, regulatory, and commercial expertise with a focused operating model designed for specialty and hospital-based products. For more information, visit . About AOP Health AOP Health Group is a global pharmaceutical enterprise with headquarters in Vienna. Its mission is to address high unmet medical needs through impactful, science-driven therapies and care models. Since 1996, AOP Health has pioneered research where limited therapies exist, to develop solutions for patients with rare diseases and severe conditions in niche therapeutic areas. Guided by the principle "Needs. Science. Trust." the AOP Health Group demonstrates its strong commitment to patients and healthcare professionals through innovation and long-term partnerships, to improve patient outcomes worldwide. For more information, visit . Media Contact Enoumena Therapeutics Inc.: media@enoumenatx.com 1 438 944-0613 To view the source version of this press release, please visit

上市批准引进/卖出

2026-09-16

·汇聚南药

天士力杀疯了！痛风1类新药冲刺，入局超70亿注射剂

精彩内容今日（9月16日），天士力产品研发迎新进展：中药1.1类新药青术颗粒提交NDA获受理，用于治疗原发性急性痛风性关节炎（湿热瘀阻证）；司美格鲁肽注射液以仿制3类申报IND获受理，原研产品2025年在中国三大终端六大市场的销售额超过70亿元。痛风1类新药冲刺上市青术颗粒源于国医大师路志正的临床经验方，主治原发性急性痛风性关节炎（湿热瘀阻证）。据悉，该新药最早于2004年12月获批临床，2025年4月完成III期临床试验，2026年9月提交NDA获受理。 2021年以来，国内仅有2款抗痛风中药1.1类创新药获批上市，分别为一力制药的虎贞清风胶囊（2021年12月）、成都华西天然药物的秦威颗粒（2024年3月），2款新药上市后在中国三大终端六大市场（统计范围详见本文末）快速放量。在研抗痛风中药新药中，天士力进展最快，青术颗粒已提交NDA在审；此外，据不完全统计，11款中药1.1类新药（以中药新注册管理办法计）处于II期临床，涉及鲁南制药、康缘药业、吉林天衡药业、苏州玉森新药开发等多家企业。国内处于II期临床及以上阶段的部分痛风中药新药来源：米内网综合数据库今年以来，天士力已有2款中药1.1类新药提交NDA获受理，分别为用于原发性急性痛风性关节炎（湿热瘀阻证）的青术颗粒，用于普通感冒（风寒证）的安体威颗粒；此外，1款中药1.1类新药提交IND获受理，为TDX105颗粒。今年以来天士力申报临床/上市的中药创新药来源：米内网中国申报进度（MED）数据库入局超70亿注射剂司美格鲁肽注射液是诺和诺德开发的一款GLP-1受体激动剂，目前已有2型糖尿病、超重/肥胖、慢性肾脏病等多个适应症获批。该药近年来在中国三大终端六大市场持续放量，2025年销售额超过77亿元，2026年上半年超过37亿元。近年来中国三大终端六大市场司美格鲁肽注射液销售情况（单位：万元）来源：米内网格局数据库除了司美格鲁肽注射液，今年以来，天士力还有9个品种以新注册分类报产获受理。其中，酒石酸匹莫范色林片、酒石酸匹莫范色林胶囊暂无企业拥有生产批文；注射用盐酸兰地洛尔仅1家企业获批生产；富马酸伏诺拉生片2025年在中国三大终端六大市场的销售额超过11亿元等。今年以来天士力以新分类报产的品种来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月16日，如有疏漏，欢迎指正！信息来源：米内网往期推荐 ! 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。喜欢的点个“看一看”和"喜欢"吧不然微信推送规则改变，有可能每天都会错过我们哦~

100 项与盐酸兰地洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01847	盐酸兰地洛尔	C07AB14	DB12212

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
室上性心动过速	加拿大	Trimedica Ltd.	2023-11-20
心律失常	中国	南京海辰药业股份有限公司	2020-12-11
心房颤动	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
心房扑动	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
心动过速	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
窦性心动过速	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05
室性心动过速	日本	Ono Pharmaceutical Co., Ltd.	2002-07-05

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	临床3期	日本	Ono Pharmaceutical Co., Ltd.	2009-06-01
心房颤动和扑动	临床2期	奥地利	AOP Orphan Pharmaceuticals GmbH	2014-10-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2026	N/A	室性心律失常	31	Landiolol	築鹽積網膚製鹽鑰鏇築(糧餘淵鑰衊築觸製鑰憲) = 顧製艱憲艱醖鬱鹹齋艱夢鹽夢廠構淵襯構鹽齋 (壓衊顧壓窪選鏇壓鹹艱 ) 更多	积极	2026-08-31
ESC2025	N/A	危重病	25	Landiolol	鬱餘構蓋積鑰衊範範餘(膚遞範顧繭齋簾製構鑰) = 憲願衊醖獵糧獵膚衊繭艱醖積範築襯壓廠窪淵 (糧廠艱淵獵憲鏇醖壓製, 87 ~ 126) 更多	积极	2025-03-14
FDA_CDER 人工标引	N/A	室上性心动过速	317	Landiolol	廠淵齋獵衊鬱積鹽蓋淵(襯齋鬱醖壓築鹹壓繭獵) = 繭鏇艱簾襯顧齋鹽膚憲艱膚襯範餘襯製夢淵鹹 (壓鏇鹽選構齋糧網構鹹 )	积极	2024-11-22
				Placebo	廠淵齋獵衊鬱積鹽蓋淵(襯齋鬱醖壓築鹹壓繭獵) = 簾遞窪鬱築範襯觸鑰糧艱膚襯範餘襯製夢淵鹹 (壓鏇鹽選構齋糧網構鹹 )
JPRN-jRCT2011180004 (ESMO2024) 人工标引	临床3期	非小细胞肺癌	404	Surgery combined with continuous infusion of landiolol	繭鹹遞遞窪壓醖網淵製(願獵製窪構齋夢積獵築) = 窪網齋衊選築網糧餘選鬱築觸築膚憲繭鬱淵壓 (構窪廠淵齋選鹽膚蓋憲, 71.8 ~ 83.8)	不佳	2024-09-14
				landiolol (Surgery alone)	繭鹹遞遞窪壓醖網淵製(願獵製窪構齋夢積獵築) = 範窪範艱齋製壓膚憲簾鬱築觸築膚憲繭鬱淵壓 (構窪廠淵齋選鹽膚蓋憲, 70.5 ~ 82.5)
EUCTR2017-002138-22-AT (Landi-SEP, Pubmed)	临床4期	-	200	兰地洛尔	鹽願網觸夢壓憲鬱築襯(積鏇鏇繭夢壓醖積膚廠) = 餘衊衊齋鬱餘齋繭網衊窪醖淵淵願鑰鹹襯憲糧 (構蓋鹽積築襯鏇鏇鬱鹽 )	积极	2024-09-01
				standard of care	鹽願網觸夢壓憲鬱築襯(積鏇鏇繭夢壓醖積膚廠) = 廠糧憲築築淵廠獵鹹遞窪醖淵淵願鑰鹹襯憲糧 (構蓋鹽積築襯鏇鏇鬱鹽 )
NCT00560209 (Pubmed \| Int J Cardiovasc Imaging)	临床2期	心肌缺血	183	Landiolol hydrochloride 0.06-mg/kg	衊鹹繭鹽遞鏇憲齋簾鹽(糧膚獵壓蓋鹹襯築憲夢) = No adverse events or reactions occurred at an incidence of 5 % or greater, confirming the safety of landiolol hydrochloride 構餘憲廠壓獵簾簾齋艱 (網齋顧鬱簾製繭齋鏇鏇 )	-	2013-06-01
				Landiolol hydrochloride 0.125-mg/kg